Episode Details

Jazz Pharmaceuticals soars with record-breaking first quarter earnings, surpassing expectations by 9.4% with a 19.1% year-over-year growth. Key drivers include Xywav, Epidiolex, Midevo, and Zepzelca. Shares skyrocket, market cap reaches $14.03 billion, and operating margins jump to 31.5%. Analysts discuss Midevos first-line use and international Epidiolex ramps. Upcoming FDA nods, study readouts, and generic competition are key focus areas.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/d30df5411eb7ead4